Acoramidis

Class
Anti-amyloid agents
Subclass
Transthyretin stabilizers
Substance name
Acoramidis
Brand names
Attruby®
Common formulations
Tablet
Dosage and administration
Adults patients
Treatment of transthyretin amyloid cardiomyopathy • Wild-type or variant
•
712 mg PO BID
Taken with or without food.
Indications for use
Labeled indications
Adults
•
Treatment of transthyretin amyloid cardiomyopathy (wild-type or variant)
Safety risks
Contraindications
Concomitant use of UDP-glucuronosyltransferase inducers or strong CYP3A inducers
Warnings and precautions
Increased serum drug levels
•
Use caution when co-administering acoramidis with drugs that are sensitive CYP2C9 substrates, as acoramidis inhibits CYP2C9 and may increase their concentrations. Monitor for toxicity.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
Renal replacement therapy
Any modality
•
No guidance available.
Hepatic impairment
Any severity
•
No guidance available.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Insufficient evidence. Report pregnancies to the BridgeBio reporting line.
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Diarrhea
Common 1-10%
•
Epigastric pain
Unknown frequency
•
↑ serum creatinine, ↓ GFR
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource